KRIBIOLISA™ Anti-Atezolizumab (TECENTRIQ) ELISA

Description

Introduction:
Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genentech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA.In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lung cancer was granted priority review. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Atezolizumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects Anti-Atezolizumab antibodies and may be used for monitoring immunogenicity.

Intended Use:
The KRIBIOLISA Anti-Atezolizumab ELISA is used as an analytical tool for quantitative determination of Anti-Atezolizumab antibodies in human serum and plasma.

Principle:
The method employs the sandwich immunoassay technique. Atezolizumab is pre-coated onto microwells. Samples or standards are pipetted into microwells and antibodies to Atezolizumab present in the sample are bound by the capture antibody. After washing microwells, HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by washing cycle. The ready to use substrate solution (TMB) is added to microwells and color develops directly proportionally to the amount of Anti-Atezolizumab present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward